Novartis

NVS Q3 2025 Earnings

Reported Oct 28, 2025 at 6:07 AM ET · SEC Source

Q3 25 EPS

$2.25

MISS 2.63%

Est. $2.31

Q3 25 Revenue

$13.91B

BEAT +0.45%

Est. $13.85B

vs S&P Since Q3 25

+23.3%

BEATING MARKET

NVS +29.4% vs S&P +6.1%

Market Reaction

Did NVS Beat Earnings? Q3 2025 Results

Novartis posted a mixed third quarter for fiscal 2025, clearing the revenue bar while falling slightly short on earnings, as robust volume-driven growth across its oncology and immunology franchises ran into the weight of generic erosion and a sizabl… Read more Novartis posted a mixed third quarter for fiscal 2025, clearing the revenue bar while falling slightly short on earnings, as robust volume-driven growth across its oncology and immunology franchises ran into the weight of generic erosion and a sizable legal charge. Revenue came in at $13.91 billion, edging past the $13.85 billion consensus by 0.45% and marking a 5.6% year-over-year gain, yet core EPS of $2.25 missed the $2.31 analyst estimate by 2.63%, weighed in part by a $443 million expense tied to a French court reversal in the Lucentis/Avastin antitrust case. The headline growth story remained the company's newer blockbusters, with Kisqali surging 69% to $1.33 billion and Kesimpta climbing 46% to $1.22 billion, while Pluvicto added further momentum after new data showed the radioligand therapy reduced the risk of disease progression or death by 28% in hormone-sensitive prostate cancer, potentially doubling its eligible patient pool. Net debt climbed to $20.40 billion, reflecting aggressive M&A spending including the $12 billion deal to acquire Avidity Biosciences.

Key Takeaways

  • Kisqali strong growth across all regions, +91% in US driven by share gains in metastatic and early breast cancer
  • Kesimpta demand increase and strong access with 155,000+ patients treated across 94 countries
  • Pluvicto sustained US demand following pre-taxane mCRPC approval with 25 countries now approved
  • Scemblix early-line indication momentum in US and Japan with 26 ex-US markets approved
  • Fabhalta market share gains in PNH globally and launch progress in IgAN and C3G in US
  • Volume contributed 16 percentage points to sales growth
  • Lower weighted average number of shares outstanding benefiting EPS
  • Lower impairment charges year-over-year improving operating income
24/7 Wall St

NVS YoY Financials

Q3 2025 vs Q3 2024, source: SEC Filings

24/7 Wall St

NVS Revenue by Segment

With YoY comparisons, source: SEC Filings

Q4 24 Q1 26
24/7 Wall St

NVS Revenue by Geography

With YoY comparisons, source: SEC Filings

Q4 24 Q1 26